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Allergic reactions can in severe cases induce a state
of circulatory shock referred to as anaphylaxis. His-
tamine, the primary mediator of this condition, is
released from immune cells, and, therefore, anaphy-
laxis has so far been considered an immune system
disorder. However, we here show that the glutama-
tergic receptor mGluR7, expressed on a subpopula-
tion of both peripheral and spinal cord neurons,
controls histamine-induced communication through
calcium-dependent autoinhibition with implications
for anaphylaxis. Genetic ablation of mGluR7, and
thus altered regulation of histamine-sensing neu-
rons, caused an anaphylaxis-like state inmGluR7/
mice, which could be reversed by antagonizing
signaling between neurons and mast cells but not
by antagonizing a central itch pathway. Our findings
demonstrate the vital role of nervous system control
by mGluR7 in anaphylaxis and open up possibilities
for preventive strategies for this life-threatening
condition.INTRODUCTION
In 1910, intravenous b-iminazolylethylamine injections were
shown to cause a sudden drop in blood pressure and respiratory
disturbance (Dale and Laidlaw, 1910). The substance was later
named histamine, and the accompanying clinical signs of a se-
vere allergic reaction are now referred to as symptoms of
anaphylaxis. Soon after, it was demonstrated that histamine
also induces peripheral symptoms such as local itch and flare
in the skin upon superficial injection (Lewis, 1927).
Histamine acts on local small diameter primary afferent neu-
rons (Ha¨germark et al., 1979; Han et al., 2006; Schmelz et al.,
1997), which release neurotransmitters from their central and pe-
ripheral terminals, to both relay pruritic information to the CNS
and to involve the immune system in host defense. Peripheral
release of neurotransmitters also leads to additional histamine
discharge from nearby mast cells (Alving et al., 1991; Lawrence370 Cell Reports 14, 370–379, January 12, 2016 ª2016 The Authorset al., 1987), which could potentially escalate an initially modest
allergic reaction into a life-threatening systemic anaphylactic
shock. Anaphylaxis is, however, an infrequent condition; the life-
time prevalence is estimated to 0.05%–2.0% (Lieberman et al.,
2006). This raises the issue whether peripheral neurons are
kept under control to prevent local allergic events from turning
into anaphylaxis by over-stimulation of the immune system.
Histaminergic itch or pruritus is a dominating local symptom of
anaphylactic shock. Pruritic events in the periphery are trans-
mitted to the CNS by different neuropeptides, such as natriuretic
polypeptide b (NPPB) (Mishra and Hoon, 2013) and calcitonin
gene-related peptide (CGRP) (Rogoz et al., 2014), which are
mainly confined within the transient receptor potential vanilloid
1 (TRPV1) lineage neurons (Cavanaugh et al., 2009; Mishra and
Hoon, 2013). Peripheral neurons with a possible role in anaphy-
laxis should therefore be confined within the histamine-sensing
NPPB/CGRP/TRPV1 population of primary afferents, and, if so,
how is the activity of these neurons regulated?
Glutamate is a fast neurotransmitter used by most, if not all,
primary afferents. Genetic ablation studies have shown that
glutamate is essential for the transmission of touch and all
modalities of pain (Rogoz et al., 2012; Seal et al., 2009), whereas
no clear evidence has been found that glutamate released from
primary afferents transmits itch. However, we and others have
demonstrated that mice with impaired release of glutamate
from peripheral neurons (Lagerstro¨m et al., 2010; Liu et al.,
2010; Rogoz et al., 2012) displayed a profound itch behavior
that could be attenuated by antihistamines (Lagerstro¨m et al.,
2010). Together, these findings suggest that glutamate released
from peripheral neurons rather controls and regulates histamin-
ergic itch instead of mediating itch. If true, what could be the
possible mechanism and how would that affect other compo-
nents during a severe allergic reaction? We set out to investigate
the neuronal component of the allergic chain to determine
whether neurons, via glutamatergic signaling, might prevent a
local allergic reaction from escalating into anaphylaxis.RESULTS
Glutamate released from primary afferents binds and activates
both ionotropic and metabotropic receptors. Group II/III
metabotropic receptors (mGluRs) were recently shown to exert
Figure 1. Activation of mGlur7 Regulates Itch,
a Local Symptoms of Anaphylaxis, through
Presynaptic Inhibition of Histamine-Sensing
Primary Afferents
(A) mGluR7-immunoreactive fibers in the dorsal part
of the spinal cord.
(B) mGluR7 and Vglut2 expression in primary afferent
neurons (n = 3, 29 sections).
(C) Intrathecal administration of the specific mGluR7
agonist AMN082 (100 mg/animal) in Vglut2f/f;Trpv1-
Cre mice (n = 8).
(D) Culture of dissociated primary afferent neurons
loaded with OGB-1 and imaged using two-
photon microscopy. The histamine and AMN082-
sensitive neuron shown in (F) is indicated with a white
arrow.
(E) Size distribution of OGB-1 loaded dorsal root
ganglia (DRG) neurons that responded to 80 mM of
histamine (black, n = 22) and non-responding neurons
(white, n = 306).
(F) Inhibition of histamine-evoked calcium response
by AMN082. Representative trace shows an in-
crease of 30% in the fluorescence signal when
histamine (80 mM) was applied to the bath. Pre-
treatment with AMN082 (10 mM) for 4 min impaired
the histamine-evoked response in the same cell.
Light gray bar indicates 15 min washing and
dark gray indicates 4 min of AMN082 treatment
(a summary of all calcium imaging data, together
with the positive controls, can be found in Fig-
ure S1B).
(G) Intrathecal injections with vehicle or the mGluR7-
specific agonist AMN082 (100 mg/animal) followed
by an intradermal injection of histamine (100 mg,
n = 6), 48/80 (10 mg, n = 6), or a-methyl serotonin
(30 mg, n = 9).
(H) Intrathecal injections with vehicle or the mGluR7-
specific agonist AMN082 followed by an intradermal
injection of the PAR2 receptor agonist SLIGRL
(100 mg, n = 13), chloroquine (10 mM, 50 ml, n = 15),
endothelin (3 pM, 50 ml, n = 16), or BAM8-22
(3.5 mM, 50 ml, n = 12). Intrathecal vehicle or
AMN082 administration in Nc/Nga mice subjected to
topical mite allergen treatments (n = 12).
(I) Histamine (100 mg, 5 ml) induced c-fos activation in
dorsal horn neurons in sedated mGluR7 transgenic
mice (n = 4, 33 sections analyzed).
(J) Single-cell PCR analysis of primary afferent neu-
rons (41% of Plcb3 mRNA expressing DRGs also
expressed mGluR7 and 58% of mGluR7 mRNA ex-
pressing DRGs expressed Plcb3 mRNA) (number of
cells analyzed = 60; mGluR7 = 211 bp, Plcb3 =
404 bp).
(K) Single-cell PCR analysis of primary afferent
neurons (52% of the Hrh1 mRNA expressing
DRGs also expressed mGluR7 and 56% of mGluR7
mRNA expressing DRGs also expressed Hrh1
mRNA) (number of cells analyzed = 109; Hhr1 =
440 bp).
(L) A schematic summarizing the findings in Fig-
ure 1. Activation of mGluR7 specifically regulates
histaminergic itch. mGluR7 is expressed in a
subpopulation of glutamatergic and histamine-
sensing primary afferents and in a subpopulation
of second-order neurons in the spinal cord.
Activation of the mGluR7 receptor in primary affer-
ents blocks histamine-induced calcium currents
(legend continued on next page)
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endogenous inhibition on primary afferents expressing TRPV1 in
rats (Carlton et al., 2011). One of these is the mGluR7 receptor
and to investigate the involvement of mGluR7 in primary afferent
regulation we performed real-time qPCR and immunohisto-
chemistry analysis, which showed that mGluR7 was expressed
in primary afferents that project to the dorsal part of the spinal
cord (Figures 1A and S1A). Interestingly, combined Vglut2 (Ve-
sicular glutamate transporter 2) in situ hybridization and mGluR7
immunohistochemistry showed that a subpopulation of mGluR7
immunoreactive neurons overlapped with Vglut2 (62%, Fig-
ure 1B), which indicates that the inhibitory group III mGluR,
mGluR7, is positioned to execute autocrine inhibition of
VGLUT2-positive primary afferent neurons. This finding promp-
ted us to perform intrathecal injections of the mGluR7-specific
allosteric agonist AMN082 to activate mGluR7 receptors in
Vglut2-deficient micewith increased histaminergic itch behavior,
which potentially could compensate for the loss of VGLUT2-
mediated signaling and thus reverse the phenotype. The intra-
thecal treatment resulted in a profound attenuation of the
scratching displayed by Vglut2-deficient mice (Figure 1C).
Thus, mGluR7 is co-expressed with Vglut2 in primary afferent
neurons, and can, when activated by an mGluR7 agonist,
reverse the histaminergic itch phenotype displayed by Vglut2-
deficient mice, suggesting that histaminergic itch is regulated
by activation of mGluR7 receptors through VGLUT2-mediated
glutamatergic transmission.
mGluR7 Selectively Regulates Histaminergic and
PLCb3-Mediated Itch through Ca2+-Dependent
Presynaptic Autoinhibition
We further characterized the role of mGluR7 in the regulation of
histaminergic itch by performing two-photon microscopy imag-
ing of histamine-induced calcium responses in dissociated pri-
mary afferents. Our analysis showed that activation of mGluR7
receptors by AMN082 could block histamine-evoked calcium re-
sponses in small diameter primary afferent neurons (Figures 1D–
1F and S1B), consequently impeding the signaling possibilities
of the neurons and providing a mechanistic explanation to how
mGluR7 can regulate histaminergic itch.
To analyze the specificity of mGluR7 in itch regulation we
combined intrathecal injection of AMN082 with a battery of pru-
retic substances in wild-type mice. Administration of AMN082
attenuated the pruritic responses evoked by histamine, com-
pound 48/80 (which promotes mast cell degranulation and
subsequent histamine release), and a-methyl serotonin (Fig-
ure 1G), whereas the pruritic responses evoked by the non-his-
taminergic agents SLIGRL, the malaria prophylaxis chloroquine,
endothelin, or bovine adrenal medulla 8-22 peptide were unaf-
fected by mGluR7 activation (Figure 1H). Furthermore, the
pruritic response displayed by inbred Nc/nga mice topically
treated withmite antigens (Suto et al., 1999), which is considered
non-histaminergic, was also indifferent to AMN082 treatment
(Figure 1H). Peripheral activation of mGluR7, through topicalin vitro, and intrathecal administration of an mGluR7 agonist in vivo inhibits his
et al., 1998).
Scale bar, 74 mm (A), 30 mm (B), 15 mm (E), and 250 mm (K). **p < 0.01. Mann-Wh
hoc test (C). All Venn diagrams were generated using the online software Venn
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the number of scratch episodes induced by compound 48/80
or histamine, indicating that the auto-feedback regulation of
histamine sensing primary afferents take place at the central ter-
minal (Figures S1C and S1D). mGluR7 is also expressed by a
subset of spinal cord neurons (Figure 1I), and, to investigate their
potential involvement in the selective regulation of histaminergic
itch, sedated mice were exposed to an intradermal histamine in-
jection, and the subsequent co-expression of the immediate
early gene c-fos and mGluR7 in the spinal cord was examined.
Histamine evoked c-fos expression in neurons positioned in
the dorsal horn where 81.4%were found to overlap with mGluR7
expression (b-gal reporter gene) (Figure 1I), indicating that
mGluR7 also has the potential of regulating histaminergic itch
at the spinal cord level, thereby providing specific regulation at
several steps of the histamine-associated line of itch.
Histamine and a-methyl serotonin-evoked itch are both
associated with activation of the intracellular enzyme PLC
(Phospholipase C) b3, which is expressed in a subpopulation
of peripheral neurons (Han et al., 2006; Imamachi et al.,
2009). Single-cell PCR analysis showed that mGluR7 partially
overlaps with Plcb3 and Hrh1 (histamine receptor 1) in primary
afferents (Figures 1J and 1K); hence, our combined data
strongly suggest that mGluR7 selectively regulates histaminer-
gic/PLCb3-associated itch through auto-feedback via inhibition
of calcium influx at the central terminal of primary afferents with
additional regulation potentially provided at the spinal level
(Figure 1L).
Loss ofmGluR7 Results in an Anaphylaxis-like Behavior
Next, we used mGluR7/ mice to further investigate the so-
matosensory functionalities involving mGluR7. Mice lacking
mGluR7 showed no detectable mGluR7 protein expression (Fig-
ure 2A), were viable, and displayed normal responses to touch,
noxious thermal, and chemical stimuli. However, they showed
attenuated responses to noxious mechanical stimuli and
increased scratching behavior compared to control littermates
(Figure 2B; for absolute values see Figures S2A–S2F). If mGluR7
is regulating histaminergic itch, an intradermal injection of hista-
mine should result in increased itch inmGluR7/ mice. Indeed,
intradermal injection of histamine resulted in increased levels of
scratching behavior in mGluR7/ mice compared to control
mice (Figures 2C and 2G), vehicle injection did not induce an
altered behavior (Figures S2G–S2I). In addition, mGluR7/
mice displayed a deviating locomotor behavior that commenced
approximately 20 min after the injection. At first, we observed a
staggering movement that was followed by almost complete
passivity and accompanied by profound hypothermia (Figures
2D, 2E, 2H, and 2I; Movie S1).
Histamine is released in the skin by mast cells (here mimicked
by a local intradermal injection) during allergic reactions. In se-
vere allergic reactions, levels of circulating histamine can rise
rapidly, which results in anaphylaxis. Notably, plasma levels oftaminergic itch specifically. The location of mGluR7 is presynaptic (Kinoshita
itney two-tailed (D and H); one-way ANOVA, Dunn’s multiple comparison post
diagram plotter (PNNL). Data are described as mean ± SEM.
Figure 2. Intradermal Histamine Injection
Induced Both Peripheral and Systemic
Symptoms of Anaphylaxis in mGluR7/
Mice
(A) mGluR7 immunoreactivity in the dorsal horn of
controls and mGluR7/ mice.
(B) The sensory phenotype displayed by
mGluR7/ mice compared to controls (n = 6-22,
see Figures S2A–S2F for statistics and an indi-
vidual representation of each test).
(C) Scratching behavior in mGluR7/ mice and
controls after an intradermal histamine injection
(100 mg).
(D) Passive behavior (no sign of locomotor activity)
in mGluR7/ mice and controls after the intra-
dermal histamine injection.
(E) Body temperature (measured in the neck re-
gion) in mGluR7/ mice and controls after the
intradermal histamine injection (n = 10mGluR7/,
13 littermate controls, see Figures S2G–S2I for
vehicle treatment).
(F) Circulating blood levels of histamine (n = 6)
and mMCP1 (n = 5) in mGluR7/ mice and
controls 60 min after the intradermal histamine
injection.
(G–I) Snapshots illustrating the different behavioral
phases (intense itch, altered locomotor behavior/
staggering gate, passivity) in the histamine-
evoked anaphylaxis-like behavior in mGluR7/
mice (Movie S1).
Scale bars, 74 mm. *p < 0.05, **p < 0.01,
***p < 0.001, Mann-Whitney two-tailed (B, F,
and G), repeated measures (RM) ANOVA, Bon-
ferroni post hoc (C–E). Data are described as
mean ± SEM.histamine in terminal blood drawn directly after the behavioral
experiments were almost twice as high in mGluR7/ mice
compared to control mice (Figure 2F). Further analysis showed
that mMCP1 levels (mouse mast cell protease 1, elevatedCell Reports 14, 370–379upon systemic mast cell mediated
release and used in the clinic to
diagnose anaphylaxis) also were mark-
edly increased (three times higher) in
mGluR7/ mice (Figure 2F), whereas
the mast cell density and number in the
skin was equal between mGluR7/ and
control mice (Figures S2J and S2K). The
systemic nature of these findings,
together with the observed increased
itch (4.3 times elevated itch behavior),
increased immobility (17.3 times more
time spent passive) and hypothermia
(maximum mean difference 3.8C; hypo-
thermia is the most common way to
monitor anaphylactic events in mice
[Doyle et al., 2013]) and indicate that the
histamine injection caused an anaphy-
laxis-like state, mediated by mast cells
(elevated mMCP1 levels), in mGluR7/mice but not in control mice. We therefore revisited and
expanded our interpretation; mGluR7-mediated regulation pre-
vents both local (histaminergic itch) and systemic symptoms of
anaphylaxis., January 12, 2016 ª2016 The Authors 373
Figure 3. mGluR7 Prevents Peripheral Neurons from Causing
Anaphylaxis via Controlled Release of Substance P
(A) Single-cell PCR analysis of primary afferent neurons (58% of the Hrh1
mRNA/mGluR7 mRNA expressing DRGs expressed Substance P mRNA)
(number of cells analyzed = 92; Substance p = 266 bp).
(B) Skin levels of Substance P in mGluR7/ mice and controls 60 min after
intradermal histamine injection (at the site of injection) (n = 4).
(C) Release of histamine from mast cells induced by two doses of the NK1R-
specific agonist GR73632 (data described as mean ± SD).
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through Control of Peripheral Release of Substance P
Howmight loss of a presynaptically expressed glutamate recep-
tor in the histamine-associated itch pathway result in a state of
anaphylaxis? Upon depolarization by histamine, primary affer-
ents release neurotransmitters in the skin through anti-dromic
depolarization of peripheral branches, transmitters that in turn
augment inflammation by recruiting and activating immune cells.
Hence, we hypothesized that activation of histamine-sensing
neurons now lacking mGluR7, which thus presumably lack pre-
synaptic autoinhibition through this receptor, should lead to
increased release of peripheral neurotransmitters. Our single-
cell PCR analysis showed that a subpopulation of mGluR7/
Hrh1 positive neurons expressed the neuropeptide Substance
P (58%, Figure 3A), connecting mGluR7, histaminergic itch,
and a peripherally released neuropeptide. Furthermore, analysis
at the histamine injection site showed that tissue levels of
Substance P were increased with 69% in mGluR7/ mice
compared to control littermates (Figure 3B), corroborating the
suggested connection between anaphylaxis-like behavior and
altered peripheral neurotransmission due to loss of mGluR7.
Upon release, Substance P can interact with mast cells to pro-
mote further histamine release (Ha¨germark et al., 1978), which
augments the inflammatory and pruritic state. We found that
mast cells express the receptor for Substance P, NK1R (Fig-
ure S3A), and that application of the NK1R-specific agonist
GR73632 results in a dose-dependent histamine release from
mast cells (Figure 3C). To investigate a mechanism where Sub-
stance P may be part of a signal linking mGluR7/HRH1 neurons,
mast cells, and anaphylaxis, we treated mGluR7/ mice and
controls with the NK1R-specific antagonist Win51708 prior to
an intradermal histamine injection (Figures 3D–3F). If this hypoth-
esis is correct, the NK1R antagonist should block Substance P
from activating mast cells and thereby prevent further mast
cell activation and histamine release and ultimately reduce or
abolish the anaphylaxis-like behavior. We found that, after
administration of Win51708, mGluR7/ mice displayed attenu-
ated itch levels, recovered faster from the passive state, and did
not display hypothermia compared to non-antagonist treated
mGluR7/ mice (Figures 3D–3F; for vehicle treatment see(D) Scratching behavior in mGluR7/ mice (black line) and controls induced
by an intradermal histamine injection (100 mg) in the presence of the NK1R
antagonist Win51708 (5 mg/kg, given 10 min prior to the histamine injection).
The red dotted line indicates the behavior induced by histamine inmGluR7/
mice without prior NK1R antagonist treatment (data shown in detail in Figures
2C–2E, n = 8).
(E) Passive behavior in mGluR7/ mice and controls induced by an intra-
dermal histamine injection in the presence of the NK1R antagonist Win51708.
(F) Neck body temperature in mGluR7/ mice and controls induced by an
intradermal histamine injection in the presence of the NK1R antagonist
Win51708 (n = 8; for vehicle treatment, see Figures S3B–S3D).
(G and H) Circulating blood levels of mMCP1 (G) and histamine (H) 60min after
the intradermal histamine injection inmGluR7/mice and controls pretreated
with the NK1R antagonist Win51708 (n = 5/treatment).
(I) Skin levels of Substance P in the injection site 60 min after the intradermal
histamine injection inmGluR7/mice and controls pretreated with the NK1R
antagonist Win51708 (n = 5/treatment).
*p < 0.05, **p < 0.01, ***p < 0.001,Mann-Whitney two-tailed (B, C, andG–I); RM
ANOVA, Bonferroni post hoc (D–F). Data are shown as mean ± SEM.
Figure 4. mGluR7 Regulates Itch but Not Systemic Symptoms of
Anaphylaxis via GRPR
(A) Scratching behavior inmGluR7/mice (black line) and controls induced by
an intradermal histamine injection (100 mg) in the presence of the GRPR
antagonist RC3095 (10 mg/kg) (n = 6). The red dotted line indicates the
behavior induced by histamine in mGluR7/ mice without prior GRPR
antagonist treatment (data shown in detail in Figures 2C–2E, n = 8).
(B) Passive behavior in mGluR7/ mice and controls induced by an intra-
dermal histamine injection in the presence of the GRPR antagonist RC3095
(10 mg/kg) (n = 6).
(C) Neck temperature in mGluR7/ mice and controls induced by an intra-
dermal histamine injection in the presence of the GRPR antagonist RC3095
(10 mg/kg) (n = 6; for vehicle treatments, see Figure S4).
(D and E) Circulating blood levels of mMCP1 (D) and histamine (E) 60 min after
the intradermal histamine injection inmGluR7/mice and controls pretreated
with GRPR antagonist (n = 6).
(F) Skin levels of Substance P in the injection site 60 min after the intradermal
histamine injection in mGluR7/ mice and controls pretreated with GRPR
antagonist (n = 5).
*p < 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney two-tailed (D–F), RMANOVA,
Bonferroni post hoc (A–C). Data are shown as mean ± SEM.Figures S3B–S3D). NK1R antagonist treatment also resulted in
reduced systemic release of the mast cell mediator mMCP1
and histamine as well as reduced tissue release of SubstanceCP inmGluR7/mice compared to non-antagonist controls (Fig-
ures 3G–3I). Thus, NK1R antagonists prevent the anaphylaxis-
like behavior in mGluR7/ mice evoked by an intradermal
histamine injection. As neurons are the only source of Substance
P in the skin (Ho¨kfelt et al., 1975), our combined data indicate
that, in histamine-evoked processes, mGluR7 controls the pe-
ripheral release of Substance P from primary afferents and
thereby subsequent activation and release of histamine from
mast cells through the NK1R, which prevents peripheral neurons
from causing anaphylaxis.
GRPR Signaling Contributes to the Mediation of
Peripheral Symptoms, Itch, but Not to Systemic
Symptoms of Anaphylaxis
Activation of histamine sensing primary afferent neurons also re-
sults in the release of neurotransmitters from central axon termi-
nals that transmit pruritic information to the spinal cord and
brain. Although there is some controversy regarding which
neurotransmitter is responsible for itch transmission from the pe-
riphery to the spinal cord (Liu et al., 2014; Mishra and Hoon,
2013), there is consensus around GRPR (gastrin releasing pep-
tide receptor) as the main downstream mediator for itch trans-
mission in the spinal cord (Mishra and Hoon, 2013; Sun et al.,
2009). Therefore, we next tested whether the increase in itch
seen inmGluR7/mice upon histaminergic provocations could
be attenuated by antagonizing the centrally expressed GRPR re-
ceptor, i.e., does histaminergic mGluR7-controlled itch, also
associated with anaphylaxis, depend on GRPR? Intrathecal
injection of the GRPR antagonist RC3095 prior to the histamine
injection resulted in drastically reduced itch levels inmGluR7/
mice compared to non-antagonist treated mGluR7/ mice
(Figure 4G; for vehicle treatments, see Figure S4), adding
anaphylaxis-associated itch to the repertoire of pruritic stimuli
that GRPRmediate in the CNS. Moreover, in light of the selective
regulatorymechanism of histaminergic itch and anaphylaxis pre-
sented here, we wondered whether central regulation of itch
might also affect systemic symptoms of anaphylaxis. However,
blockade of GRPR did not prevent the systemic anaphylaxis-
like behavior; RC3095-treated mGluR7/ mice showed similar
levels of passivity and hypothermia as non-antagonist treated
mGluR7/ mice (Figures 4B and 4C). Furthermore, GRPR
antagonist treatment did not prevent the rise of circulating
mMCP1 and tissue levels of Substance P (Figures 4D–4F).
Thus, we suggest that, whereas mGluR7-regulated anaphylactic
itch is dependent on central transmission via GRPR, regulation of
systemic symptoms of anaphylaxis is not.
DISCUSSION
In histaminergic itch transmission, primary afferents provide an
ascending signaling pathway between the site of release in the
periphery and the CNS, which results in the awareness of itch
and a targeted scratching behavior. Primary afferents also
possess branched peripheral nerve endings, providing hista-
mine-sensitive neurons with the ability to activate the immune
system through local neurotransmitter release in the affected
tissue (Ha¨germark et al., 1978). Such release produces the
characteristic flare response associated with allergic reactions.ell Reports 14, 370–379, January 12, 2016 ª2016 The Authors 375
Figure 5. Histamine-Sensing mGluR7 Neu-
rons Express Nppb and Cgrp
(A) Single-cell PCR analysis ofNppb,mGluR7, and
Hrh1 mRNA expression in primary afferent neu-
rons. The analysis showed that 57% of mGluR7
mRNA/Hrh1 mRNA expressing neurons also ex-
pressNppbmRNA (number of cells analyzed = 98;
Nppb = 280 bp).
(B) Single-cell PCR analysis of Cgrp,mGluR7, and
Hrh1 mRNA expression in primary afferent neu-
rons. The analysis showed that 85% of mGluR7
mRNA/Hrh1 mRNA expressing neurons also ex-
press CgrpmRNA (number of cells analyzed = 93,
Cgrp = 410 bp).
(C) Schematic drawing summarizing our findings,
which show that mGluR7 regulates both periph-
eral and central aspects of histaminergic-evoked
primary afferent neurotransmission, with implica-
tions for anaphylaxis. Besides binding to the
NK1R, Substance P has recently been shown to
interact with MRGPRB2 (McNeil et al., 2015),
which also can lead to degranulation of mast cells.An mGluR7-dependent control of primary afferents should thus
have two consequences for histamine-induced neurotransmis-
sion: altered central transmission, affecting the scratching
behavior, and altered peripheral transmission influencing the im-
mune system. We here present data supporting a model for how
mGluR7 might regulate histaminergic transmission, both periph-
erally and centrally, and how the regulation affects the symptoms
of the histamine-involved disorder anaphylaxis.
mGluR7 Regulates the Peripheral Immune System via
Substance P and NK1R in Allergic Events
We found that genetic ablation of mGluR7 altered histamine-
induced peripheral transmission from primary afferents as hista-
mine-injected mGluR7/ mice displayed increased levels of
Substance P in the innervated tissue; a peptide whose mRNA
we showed to be expressed by mGluR7/HRH1 neurons and
that can degranulate cultured mast cells via the NK1R. We
thus conclude that Substance P constitutes a link between
mGluR7-regulated primary afferents and mast cells in the im-
mune system that can evoke the systemic symptoms of anaphy-
laxis. Both mast cells and basophils can release histamine upon
binding of Substance P, and therefore an additional influence
from basophils cannot be excluded. However, only mast cells
release mMCP1, which together with histamine is used as a
clinical biomarker for anaphylaxis. We found elevated levels
of circulating histamine as well as mMCP1 in blood from
mGluR7/ mice, suggesting that the anaphylaxis-like symp-
toms displayed by mGluR7/ mice are mediated by mast cells
(Figure 5A).
Substance P can also activate mast cells through interaction
with the MRGPRB2 protein, recently identified as the receptor
for basic secretagogue compounds (McNeil et al., 2015), and
therefore additional effects from interaction between the
MRGPRB2 protein and Substance P cannot be excluded. Our
findings, however, suggest that specific interactions with the
NK1R, via the use of an NK1R agonist can degranulate mast376 Cell Reports 14, 370–379, January 12, 2016 ª2016 The Authorscells. Furthermore, the anaphylaxis-like behavior in histamine-
provoked mGluR7/ mice could be reversed by administrating
an NK1R-specific antagonist, which supports that mGluR7-
regulated primary afferents mainly communicate with mast cells
via the NK1R (Figure 5A). In further support, treatment with a
Substance P antagonist has been shown to attenuate symptoms
of allergy-induced anaphylaxis in the passive cutaneous anaphy-
laxis model (Siebenhaar et al., 2008).
mGluR7 Regulates the CNS in Allergic Events
The histamine-sensing primary afferents also communicate with
the CNS via release of neurotransmitters from their central termi-
nals, which affects our perception of a dominating symptom of
anaphylaxis, histaminergic itch. Previous studies have shown
that peripheral removal of VGLUT2 results in a profound hista-
minergic itch phenotype, suggesting that histamine-induced
itch is regulated by the neurotransmitter glutamate (Lagerstro¨m
et al., 2010). Also, group II/III mGluRs, to whichmGluR7 belongs,
were recently shown to exert endogenous inhibition on primary
afferents expressing TRPV1 in rat (Carlton et al., 2011). Here,
we show that presynaptic activation of mGluR7 receptors on his-
tamine-sensing primary afferents inhibits calcium influx suggest-
ing that the mGluR7 receptor and glutamate regulate the
neuronal activity of these neurons. In support of this hypothesis,
activation of mGluR7 in hippocampal and cortical neurons has
been demonstrated to reduce presynaptic Ca+2 influx, resulting
in auto-inhibitory reduction of glutamate release (Martı´n et al.,
2007; Milla´n et al., 2002). CGRP and NPPB have been identified
as potential candidates for transmitting histaminergic itch from
the periphery to the spinal cord (Rogoz et al., 2014; Mishra and
Hoon, 2013). If glutamate and mGluR7 regulate histaminergic
itch through auto-feedback inhibition, mGluR7 and HRH1 should
co-localize with these itch-transmitting peptides. Indeed, our
single-cell analysis showed that both Nppb and Cgrp are ex-
pressed in the Hrh1/mGluR7 expressing population of primary
afferents (Figures 5B and 5C). Thus, similar to the peripheral
regulation of Substance P neurotransmitter release, mGluR7 and
glutamate also have the potential to regulate the central release
of neurotransmittors (NPPB and/or CGRP) from histamine-
sensing primary afferents, thereby exerting a role in the central
transmission of histaminergic itch (Figure 5A). Interestingly,
mGluR7, Nppb, Cgrp, Substance P, and Hrh1mRNA transcripts
can all be found in a recently identified subpopulation of primary
afferents, the NP2 class (Usoskin et al., 2015). Together, these
data suggest that NP2 neurons are responsible for the regulation
of the peripheral nervous system in anaphylaxis.
Our data suggest that the regulation of primary afferents by
mGluR7 can explain both the systemic and local symptoms of
anaphylaxis displayed by the mGluR7/ mice. However, other
parts of the nervous system could have additional effects in
the mGluR7-mediated neuronal regulation of symptoms of
anaphylaxis. mGluR7 is also expressed in a subpopulation of
second-order neurons in the spinal cord, which could influence
the itch phenotype displayed by mGluR7/ mice. Intradermal
injection of histamine in sedated mice led to c-fos activation in
the dorsal spinal cord where 81.4% of the neurons also ex-
pressed mGluR7. These data indicate that mGluR7 can regulate
the local symptom of anaphylaxis, histaminergic itch, both
through presynaptic autoinhibition of primary afferents and spi-
nal cord interneurons.
mGluR7 Regulates the Neuronal Response to Prolonged
Sensory Stimuli, Such as Anaphylaxis-Associated Itch,
but Not Acute Noxious Heat
Histaminergic itch transmitted by primary afferent neurons de-
pends on the signal transduction pathway involving the noxious
heat receptor TRPV1 (Caterina et al., 1997; Imamachi et al.,
2009), which shows substantial overlap withmGluR7 (Figure S5).
The overlap and shared signaling pathway would indicate that
mGluR7 also regulates acute thermal thresholds. However, this
is not the case. Our data show that mGluR7/ mice do not
detect noxious heat in a significantly different manner from their
littermate controls, which is in agreement with previous findings
(Masugi et al., 1999; Stachowicz et al., 2008). These findings
could be due to the fact that mGluR7 and Trpv1 do not overlap
completely and/or that mGluR7 may only regulate more persis-
tent stimuli because of the low affinity for glutamate (Mitsukawa
et al., 2005), which requires a prolonged intense release of gluta-
mate to inhibit the presynaptic neuron. Why would we have
developed an mGluR7-dependent endogenous mechanism for
regulating histamine-sensing neurons, especially since these
neurons also partially transmit noxious thermal pain? How could
signaling evoked by intense histaminergic stimuli be restrained
but not the essential perception of acute noxious heat, which
would be devastating for the organism if it were silenced? We
speculate that the low affinity of the receptor to glutamate results
in a response only after prolonged stimuli. Acute/short term stim-
uli, such as the initial itch sensation from an infecting parasite or
acute noxious heat (Masugi et al., 1999; Stachowicz et al., 2008),
is detected. However, prolonged allergic events will cause
extended activation of the neuronal population and thus sus-
tained release of glutamate, which in turn initiates the regulatory
mechanism to prevent anaphylaxis. In support of this hypothe-
sis, activation of mGluR7 has been shown to regulate states ofCprolonged pain such as Carrageenan-induced hypersensitivity
to heat (Dolan et al., 2009) and chronic constriction injury-
induced allodynia (Osikowicz et al., 2008).
Previously, anaphylaxis has been regarded as a result of an
over-active or defective immune system. We now present data
suggesting that dysfunctional regulation of primary afferents
can cause anaphylaxis. Furthermore, we propose a mechanism
for its regulation, through glutamatergic auto-feedback of hista-
mine-associated mGluR7-expressing neurons. Future studies
should investigate whether individuals susceptible to anaphy-
lactic shock, or allergens, carry defects in this mechanistic chain
of events. Further, the development of mGluR7 agonists may
provide possibilities to prevent this life-threatening condition.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
The Vglut2f/f;Trpv1-Cre mice were generated through a cross between Trpv1-
Cre mice (C57BL/6NCrl*DBA/2) and Vglut2f/f mice (Sv129/R1 * C57BL/6).
mGluR7/ mice (129P2/OlaHsd * C57BL/6) were purchased from the
MMRRC repository. Nc/Nga mice (Nc/NgaTndCrlj) were purchased from
Charles River Laboratories. C57BL/6 mice were bought from Taconic.
Immunohistochemistry
Antibodies were rb anti-b-galactosidase (b-gal) 1:5,000 (8559761, Cappel), rb
anti c-fos 1:200 (sc-52-G, Santa Cruz Biotechnology), rb anti-mGluR7 1:1,000
(Millipore, 07-239), goat anti-chicken Alexa 488 1:400, donkey anti-rb Alexa
488 1:400, donkey anti-goat RRX 1:400, and goat anti-rb Alexa 647 1:400
(all from Invitrogen).
Calcium Imaging
First, the prepared cultures were loadedwithOregon green Bapta 488 (OGB-1)
(Molecular Probes) and then incubated at 37C for 1 hr in the dark. After the
incubation period, each dish was washed two times with HEPES. Two-photon
calcium imaging was then performed through a 870-nm excitation wavelength
laser (Modelocked Ti:Sapphire laser system [Coherent]), and the signal was re-
corded using a 403water-immersion objective (Plan Apochromat; 1 numerical
aperture [NA]; Zeiss). A LabView custom-made software HelioScan (Langer
et al., 2013) was used to acquire the signal in a frame rate of 2 Hz.
Behavior
All animal procedures were approved by the local ethical committee in
Uppsala and followed the Directive 2010/63/EU of the European Parliament
and of the Council, The Swedish Animal Welfare Act (SFS 1988:534), The
Swedish Animal Welfare Ordinance (SFS 1988:539), and the provisions
regarding the use of animals for scientific purposes: DFS 2004:15 and SJVFS
2012:26.
For detailed information, see the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one movie and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.12.033.
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